
ORIGINAL RESEARCH

RETRACTED ARTICLE: IncRNA differentiation antagonizing nonprotein coding RNA overexpression accelerates progression and indicates poor prognosis in pancreatic ductal adenocarcinoma



General Surgery Department, Dazhou Central Hospital, Dazhou 635000, Sichuan, China

*These authors contributed equally to this work



Correspondence: Jun Zhang General Surgery Department, Dazhou Central Hospital, No 56, South YueMiao Street, Dazhou 635000, Sichuan, China Tel +86 I 589 299 6013 Email zjdazhou@sohu.com



Background: IncRNA differentiation antagenzing new otein coding RNA (IncRNA DANCR) has been suggested to play an oncogenitate in multiple angles. However, to the best of our knowledge, the clinical significance and role a DANCR in pancreatic ductal adenocarcinoma (PDAC) has not been illuminated till now. The present study aims to identify the functional role of DANCR in PDAC.

Methods: The expression DANCR was detected in PDAC cells and tissues. The correlation of DANCR expression and DAC clinic ahological features was analysed. Kaplan-Meier method was used to depict the rall set and shorter progression-free survival (PFS) of PDAC p d Log-rank test was performed to analyse the difference. Univariate iem X recession odel were utilized to analyse the risk factors for prognosis. and multivariate C Transy ay and atrigel assay were conducted to detect the effect of DANCR on the ation an f PDAC cells, respectively. Colony formation assay and Cell Counting mi nvasio 8 (CCJ www.e performed to evaluate the function of DANCR on proliferation. The ins of DANCR exerting its function were also explored. mec

ANCR was revealed to promote PDAC progression, with relatively higher expression Results. levels in PLC cell lines and tissues. Correlation analysis of the clinicopathological features DANCR expression found that high DANCR expression was statistically correlated with ar invasion (P=0.013), advanced T stage (P=0.005), lymph node metastasis (P<0.001) vas and advanced TNM stage (P<0.001). Notably, survival analysis discovered that high DANCR expression predicted lower OS rate and shorter PFS period. In addition, high DANCR expression was identified as an independent risk factor for poor OS (HR=1.199, 95% CI=1.113-1.290, P<0.001) and PFS (HR=1.199, 95% CI=1.114-1.290, P<0.001) of PDAC. Moreover, in vitro assays detected that the migration and invasion of Panc1 cells with DANCR deficiency were significantly suppressed in the Transwell assay and the Matrigel assay. However, the motility of BxPC3 cells with DANCR overexpression was obviously increased. In addition, the loss of DANCR suppressed the proliferation of Panc1 cells in the CCK-8 assay and the colony formation assay, while ectopic expression of DANCR in BxPC3 cells promoted the proliferation. Besides, microRNA-33a-5p/AXL signaling pathway may be involved in mediating the function of DANCR.

Conclusion: Overexpression of lncRNA DANCR in PDAC is associated with cancer progression and predicts poor OS and PFS. DANCR could promote the proliferation and metastasis of PDAC cells. DANCR may serve as a potential prognostic marker and therapeutic target in PDAC.

Keywords: IncRNA DANCR, pancreatic cancer, prognosis, proliferation, metastasis

7955

© 2018 Chen et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, large acparatol. But any commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, large see paragraph 4.2 and 5 of our Terms (http://www.dovepress.com/terms.php).

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. The 5-year survival rate increased only from 3% to 8% over the past 40 years.¹ The reasons for such dismal survival include lack of early detection, presentation at late stages and inadequate current therapies.² Most PDAC patients lack specific symptoms at early stage, and only about 20% of PDAC patients have the opportunity to receive curative resection. Carbohydrate antigen (CA) 19-9 is the most commonly used tumor marker for the diagnosis of PDAC in clinical practice; the median sensitivity and specificity of CA19-9 for the diagnosis are only 75.5% and 77.6%, respectively, with a low positive predictive value of 0.5%-0.9%, which does not qualify it as a useful screening parameter.3-5 No conventional biomarkers have proven to be a specific and reliable tool for the early detection of PDAC.⁵ Considering the complexity of cancer biology, combination of different markers as diagnostic or prognostic indices appears promising. Therefore, more explorations are needed to validate novel diagnostic and prognostic markers.

IncRNAs are defined as endogenous cellular RNAs of more than 200 nucleotides in length and lack an open reading frame of significant length (<100 amino acids).⁶⁻⁸ lncRNAs are found in almost every branch of life and involved in numerous importa biological phenomena, such as imprinting genomic loci, shaping chromosome conformation and allosterically regul enzymatic activity.^{8,9} Specific patterns of lncRNA ex ession of brdinate cell state, differentiation, development and rase interestingly, the aberrant expression of CRNAS. iscovered to be involved in cancer initiation ar ression thro h tran-^{13,14} In addition, scriptional and posttranscriptional regulation mounting evidence showed at lncRNAs are pressed in a ch make hem an ideal biomarker for tissue-specific manner, w cancer diagnosis and thera, arget.¹⁵ RNAs have shown uti the composizion of bladder potential as biom cancer, prost . cancer astric cal, r, pancreatic cancer, breast pes.¹⁶ cancer and n v ot¹

IncRNA differentiation antagonizing nonprotein coding RNA (DANCR) was st identified as an 855 bp lncRNA downregulated during differentiation by Kretz et al.¹⁷ Subsequently, Yuan et al¹⁸ reported that DANCR could increase the stemness features and predict prognosis in hepatocellular carcinoma. After that, the oncogenic role of DANCR in gastric cancer,¹⁹ colorectal cancer,²⁰ prostate cancer²¹ and lung adenocarcinoma²² has been reported. However, the clinical significance and role of DANCR in PDAC has not been illuminated yet.

Our study aimed to measure the expression level of DANCR in PDAC cell lines and tissues, and the significance of DANCR in the clinical progression of PDAC was verified. Moreover, the prognostic value of DANCR was analyzed. In addition, the functional role of DANCR in proliferation and metastasis of PDAC was defined by in vitro assays.

Materials and methods Cell lines and cell culture

The human pancreatic cancer cell lines Panc1, Panc28, AsPC1, MiaPaCa2 and BxPC3 and the human pancreatic ductal epithelial cell line HPDE were purchased from the American Type Culture Collection (ATCC, Manassas, Values). Cells were cultured in Roswell Park Memoria institute-10 medium EM (Hyclor (AsPC1, BxPC3 and HPDE) or D. Thermo A, USA Panc1, Fisher Scientific, Waltham anc28 and MiaPaCa2) supplemented ath 10% BS (H, 1/2e), 100 U/mL penicillin and 100 mg/mL rept Aycin. All cells were cultured abator when 5% CP at 37°C. in a humidified in

ectopic overexpression All the size and DAN plasmid used in the urrent study were synthesized by anna (Shangha, China). Transfection was con-Gener d using the Lipofectamine[™] 2000 transfection reagent duc (Th mo Fisher Sectific) according to the protocol recomby the canufacturer. The transfected cells were mend lized for nurther investigations 48 hours later.

Clinical specimens

he 206 PDAC tissues and paired tumor adjacent tissues were ollected from surgical resections at the general surgery department of Dazhou Central Hospital. The tumor-adjacent tissues, defined as normal tissues in routine pathological results, were obtained 2 cm away from the PDAC tissues. These tissues were divided into two groups, the low DANCR expression group (n=120) and the high DANCR expression group (n=86), with the mean DANCR expression level serving as the cutoff value. The clinicopathological characteristics of the PDAC patients are summarized in Table 1. All the patients involved in the current study received radical surgical resection without preoperative chemotherapy or radiotherapy. The collected specimens were snap frozen in liquid nitrogen and stored at -80°C until being used. Tissue specimen collections were made with full informed consent of all patients following institutional ethical guidelines that were reviewed and approved by the ethics committee of Dazhou Central Hospital.

RNA isolation. RNA extraction and quantitative real time (gRT)-PCR

Total RNA was extracted from tissues or cultured cells using TRIzol reagent (Thermo Fisher Scientific). One microgram of

Table I Relationship between IncRNA DANCR expression and
clinicopathological characteristics of PDAC

Parameters	No of patients (n=206)	DANCR (high/low)	P-value	
Age			0.067	
<60 years	90	44/46		
\geq 60 years	116	42/74		
Gender			0.133	
Male	132	50/82		
Female	74	36/38		
CEA			0.675	
<4.5 μg/mL	154	63/91		
≥4.5 μg/mL	52	23/29		
CA19-9			0.965	
<37 U/mL	89	37/52		
≥37 U/mL	117	49/68		
Tumor location			0.686	
Head and neck	135	55/80		
Body and tail	71	31/40		
Grade			0.571	
Well + moderate	141	57/84		
Poor + undifferentiated	65	29/36		
Size			0.195	
<4 cm	121	46/75		
\geq 4 cm	85	40/45		
Neural invasion			0.586	
No	86	34/52		
Yes	120	52/68		
Vascular invasion			0. 3	
No	112	38/74		
Yes	94	48/46		
Lymphatic invasion			0.511	
No	69	(38		
Yes	137	55,		
T stage			0.005	
TI + T2	138	49/89		
T3 + T4	66	37/29		
Lymph node metastasis			<0.001	
No	121	36/2		
Yes	87	50/35		
Distant metastasis			0.435	
No	200	85/115		
Yes		3/2		
TNM str			<0.001	
Early sta	113	35/78		
Advanced su s (>IIA)	92	51/41		

Abbreviations: DA, R, differentiation antagonizing nonprotein coding RNA; PDAC, pancreatic ductar adenocarcinoma; CEA, carcinoembryonic antigen.

total RNA was reversely transcribed in a final volume of 20 μ L under standard conditions using PrimeScript RT Reagent Kit (TaKaRa, Dalian, China). After the reverse transcription, 1 μ L of the complementary DNA was used for subsequent reactions. The qRT-PCR reactions were performed using an ABI7500 System (Thermo Fisher Scientific) and SYBR Green PCR Master Mix (TaKaRa). GAPDH was used as endogenous

control. The primers used in this study are as follows: DANCR: forward 5'-GCCACTATGTAGCGGGTTTC-3', reverse 5'-ACCTGCGCTAAGAACTGAGG-3'; GAPDH: forward 5'-TGCACCACCAACTGCTTAGC-3', reverse 5'-GGCATGCACTGTGGTCATGAG-3'. All assays were performed in triplicate. Statistical analyses of the results were performed using the $2^{-\Delta\Delta Ct}$ relative quantification method.

Transwell assay and Matrigel assay

The transfected cells and corresponding control cells (1×10^5) were suspended with fresh medium (200 uL) and added into the upper side of Transwell chapiers (8 µm, re size; BD Biosciences, San Jose, CA, USA, coated (in Tenswell assay) or coated (in Matrigel as:) with LuL Matrigel (BD Biosciences). The bottom elimber was filled wir medium containing 20% FBS, woh by as memo-attractant. After 24-hour incubation. p imigrate cells in the upper chamber were hen the mig. the cells in the downside of the removed chamber were fix 1 with 4% paraformaldehyde for 30 minutes ed with Gie. 3 (1:10 dilution) for 30 minutes at room an mperature. The cell numbers were counted in five random elds of each hamber under the microscope.

formation assay

Co.

policate cultures of transfected PDAC cells and corresponding control cells (500 cells/well) were seeded in six-well plates and maintained at 37°C in a 5% CO₂ atmosphere, and the fresh medium was added every 2 days. Two weeks later, formed colonies were fixed with methanol and stained with 0.1% crystal violet (Sigma-Aldrich Co., St Louis, MO, USA). Colonies with more than 50 cells were counted. Each experiment was repeated in triplicate.

Cell Counting Kit-8 (CCK-8) assay

The CCK-8 (Dojindo, Kumamoto, Japan) assay was conducted according to the manufacturer's protocol. Briefly, transfected PDAC cells and corresponding control cells (2×10^4 cells per well) were plated in 24-well plates in triplicate. CCK-8 reagent was added at the indicated time points (0, 24, 48, 72 and 96 hours), and the cells were cultured for a further 4 hours at 37°C. Absorbance at 450 nm was measured using a microplate reader.

Statistical analyses

All statistical analyses were performed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA). Continuous data were analyzed using an independent *t*-test between two groups. Categorical data were analyzed using the chi-squared test or Fisher's exact test as appropriate. Overall survival (OS)

rate and progression-free survival (PFS) rate were calculated using the Kaplan–Meier method and the log-rank test for comparisons. Multivariate survival analyses were performed on all factors that were significant in univariate analyses using the Cox regression model. A *P*-value of <0.05 was considered to represent statistical significance.

Results

DANCR overexpression implicates cancer progression in PDAC

Comparison of DANCR expression in PDAC cell lines with human pancreatic ductal epithelial cell line, HPDE, was carried




Figure I DANCR overexpression implicates cancer progression in PDAC.

Notes: (A) Expression of DANCR in five PDAC cell lines (BxPC3, Panc28, AsPC1, MiaPaCa2 and Panc1) and human pancreatic ductal epithelial cell line, HPDE, was measured by qRT-PCR assay. (B) The expression level of DANCR in PDAC tissues relative to paired tumor-adjacent tissues was detected by qRT-PCR assay and calculated. (C) The expression level of DANCR in PDAC tissues with vascular invasion evaluated by qRT-PCR assay was compared with PDAC tissues without vascular invasion. (D) The expression level of DANCR in PDAC tissues with T-stage T1 and T2 detected by qRT-PCR assay was compared with PDAC tissues with T-stage T3 and T4. (E) The expression level of DANCR in PDAC tissues with Inde metastasis detected by qRT-PCR assay was compared with PDAC tissues with T-stage T3 and T4. (E) The expression level of DANCR in PDAC tissues with Imph node metastasis detected by qRT-PCR assay was compared with PDAC tissues without wascular invasion. (F) The expression level of DANCR in PDAC tissues with TNM early stages detected by qRT-PCR assay was compared with PDAC tissues with TNM advanced stages. *P<0.05. Abbreviations: DANCR, differentiation antagonizing nonprotein coding RNA; PDAC, pancreatic ductal denocarcinoma; qRT-PCR, quantitative real time polymerase chain reaction.

out by the qRT-PCR assay, which revealed that DANCR was overexpressed in five PDAC cell lines compared with HPDE cells (P < 0.05; Figure 1A). For further determination of the expression pattern of DANCR in PDAC, DANCR expression was evaluated in 206 PDAC tissues and paired tumor-adjacent tissues. Interestingly, PDAC tissues displayed a notably higher DANCR expression level than paired tumor-adjacent tissues (P < 0.05; Figure 1B). The PDAC tissues were dichotomized with the mean expression level of DANCR serving as the cutoff value, including the high DANCR expression group (n=86) and the low DANCR expression group (n=120). The relationship between DANCR expression and clinicopathological features of PDAC was statistically analyzed, which found that high DANCR expression correlated with vascular invasion (P=0.013), advanced T stage (P=0.005), lymph node metastasis ($P \le 0.001$) and advanced TNM stage (P<0.001; Table 1). In addition, patients with vascular invasion (Figure 1C), advanced T stage (Figure 1D), lymph node metastasis (Figure 1E) and advanced TNM stage (Figure 1F) exhibited much higher DANCR expression level. Overall, high DANCR expression indicates advanced tumor stage, and DANCR may promote the clinical progression of PDAC.

DANCR overexpression indicates po prognosis in PDAC

To evaluate the prognostic significance of DAMEA in PDAME the OS rate and PFS rate of PDAC patients with high DANC expression and low DANCR expression were done Dowith the Kaplan–Meier analysis and compared with the log-rank test. As shown in Figure 2A and a patients with the DANCR expression had a significantly higher OS rate and PFS rate. Univariate analysis found that high DANCR expression (HR = 1.224, 95% CI = 1.120 - 1.302, P < 0.001) was one of the six risk factors related to poor OS of PDAC (Table 2). Besides, multivariate analysis further identified high DANCR expression as an independent risk factor of poor OS of PDAC (HR =1.199, 95% CI =1.113-1.290, P<0.001; Table 2). Similarly, univariate analysis found that high DANCR expression (HR =1.219, 95% CI =1.146-1.296, P<0.001) was one of the six risk factors related to poor PFS of PDAC (Table 3). In addition, multivariate lysis further identified high DANCR expression an independent risk factor of poor PFS of PDAC (HR = 99, 95% Cl 1.114–1.290, P < 0.001; Table 3). Table 1 together high D ANCR expression predicts poor OS and PFS and h, V ANCR expression is an independent New fact, of poor OS and PFS.

DANCE cceleration detastasis and proliferation of PDAC cells

The active entropy of the migration of PDAC. The following active would try to detect the functional role of DANCR in metasatists and proliferation of PDAC. The expression of a DCR was silenced and upregulated in Panc1 cells and BxPC3 cells, respectively (Figure 3A and B). The Transwell assay and the Matrigel assay found that the loss of DANCR obviously inhibited the migration and invasion of Panc1 cells, respectively (Figure 3C). Therefore, the migration and invasion abilities were evidently accelerated after DANCR




Figure 2 DANCR overexpression indicates poor prognosis in PDAC.

Notes: (A) The OS rate of PDAC patients with low DANCR expression and high DANCR expression was depicted with the Kaplan–Meier analysis and compared with the log-rank test. (B) The PFS rate of PDAC patients with low DANCR expression and high DANCR expression was depicted with the Kaplan–Meier analysis and compared with the log-rank test.

Abbreviations: DANCR, differentiation antagonizing nonprotein coding RNA; OS, overall survival; PDAC, pancreatic ductal adenocarcinoma; PFS, progression-free survival.

Chen et al

Parameters	Univariate analysis			Multivariate analysis		
	HR	95% CI	P-value	HR	95% CI	P-value
Age: \geq 60 years vs <60 years	0.837	0.54-1.181	0.311			
Gender: male vs female	1.446	0.992-2.109	0.055			
CEA: \geq 4.5 µg/mL vs <4.5 µg/mL	0.940	0.631-1.400	0.760			
CA19–9: <37 U/mL vs ≥37 U/mL	1.030	0.729-1.455	0.867			
Tumor location: head and neck vs body and tail	1.101	0.765-1.585	0.604			
Grade: well + moderate vs poor	1.027	0.717-1.469	0.886			
Size: $<4 \text{ cm vs} \ge 4 \text{ cm}$	0.952	0.670-1.351	0.783			
Neural invasion: yes vs no	1.179	0.834-1.667	0.350			
Vascular invasion: no vs yes	1.528	1.084-2.154	0.015	1.463	1.033-2.072	0.032
Lymphatic invasion: no vs yes	0.763	0.535-1.089	0.137			
T stage: T1 + T2 vs T3 + T4	1.863	1.310-2.648	0.001	0.964	.511–1.818	0.909
Lymph node metastasis: no vs yes	1.795	1.275-2.529	0.001	1.344	0.550–3.285	0.516
Distant metastasis: no vs yes	11.172	4.320-28.890	<0.001	6.	99–16.213	<0.001
TNM stage: early stages (\leq IIa) vs advanced stages ($>$ IIa)	1.621	1.151-2.283	0.006	ه43	0.3. 1.885	0.677
DANCR: high vs low	1.224	1.150-1.302	<0.001	1.199	1.113-100	<0.001

Abbreviations: DANCR, differentiation antagonizing nonprotein coding RNA; OS, overall survival; PDAC, pancrezes due

overexpression in BxPC3 cells (Figure 3D). Furthermore, the colony formation assay and the CCK-8 assay found that DANCR deficiency notably decreased the colony numbers and OD value of Panc1 cells (Figure 4A and B). Accordingly, DANCR ectopic expression remarkably increased the colony numbers and OD value of BxPC3 cells (Figure 4C and D). These results confirmed that DANCR could accelerate the metastasis and proliferation of PDAC cells.

DANCR may function through up egulating AXL via microRNA-33a-5p inh hition

DANCR has been reported to computatively to fact with miR-634 and miR-33a-5p, thus regulated downstread protein expression in glioma and osteosarcoma, he pectively.^{23,24} The

5p was also investigated expression of AR 34 and miRin PDAC cells by qRN CR. The results showed that miR-33a-5py s not ceably down gulated in BxPC3 with DANCR xpression (Figure 5A), accompanied with increased ove ssion of AX (Figure 5B), the downstream protein of exp miR-5p. Ac ordingly, when DANCR was silenced in nc1 cells, me expression of miR-33a-5p was upregulated , while the expression of AXL was significantly (\mathbf{F}) suppressed (Figure 5D). However, the expression of miR-34 and its downstream protein, RAB1A, was not changed when DANCR was knocked down or overexpressed (Figure 5A–D). These evidences indicate that DANCR may also function through upregulating AXL via microRNA-33a-5p inhibition in PDAC cells.

de

arcinoma

Table 3 Univariate and medivariate palysis of clinicopathologic features for PFS of PDAC patients

Parameters	Univariate analysis			Multivariate analysis		
	HR	95% CI	P-value	HR	95% CI	P-value
Age: \geq 60 years <60 years	0.863	0.612-1.218	0.402			
Gender: male female	1.444	0.991-2.105	0.056			
CEA: ≥4.5 μg/m 5 μg/m∟	0.950	0.638-1.415	0.801			
CAI9–9: <37 U/mL ≥37 U/mL	0.981	0.695-1.385	0.913			
Tumor location: head an neck vs body and tail	1.161	0.810-1.664	0.416			
Grade: well + moderate vs poor	1.056	0.739-1.508	0.765			
Size: \leq 4 cm vs \geq 4 cm	0.992	0.699-1.406	0.963			
Neural invasion: yes vs no	1.165	0.824-1.646	0.388			
Vascular invasion: no vs yes	1.416	1.004-1.996	0.047	1.343	0.948-1.903	0.097
Lymphatic invasion: no vs yes	0.795	0.556-1.136	0.208			
T stage: TI + T2 vs T3 + T4	1.775	1.245-2.530	0.002	0.892	0.488-1.631	0.711
N stage: N1 vs N0	1.769	1.256-2.493	0.001	1.405	0.595-3.315	0.438
M stage: M1 vs M0	10.762	4.170-27.780	<0.001	6.081	2.292-16.131	<0.001
TNM stage: early stages (\leq IIa) vs advanced stages ($>$ IIa)	1.593	1.131-2.244	0.008	0.831	0.379-1.821	0.643
DANCR: high vs low	1.219	1.146-1.296	< 0.00 I	1.199	1.114-1.290	<0.001

Abbreviations: DANCR, differentiation antagonizing nonprotein coding RNA; PDAC, pancreatic ductal adenocarcinoma; PFS, progression-free survival.




Figure 3 DANCR accertates metastasis of PDAC cells.

Notes: (**A**) The relative expression level of DANCR in Panc1 cells after DANCR interference was determined by qRT-PCR assay. (**B**) The relative expression level of DANCR in BxPC3 cells after DANCR overexpression was confirmed by qRT-PCR assay. (**C**) The migration and invasion abilities of Panc1 cells with DANCR silencing were analyzed with Transwell assay and Matrigel assay, respectively (right panel). Typical images are shown in the left panel. (**D**) The migration and invasion abilities of BxPC3 cells with DANCR overexpression were revealed with Transwell assay and Matrigel assay, respectively (right panel). Typical images are shown in the left panel. (**D**) The migration and invasion abilities of BxPC3 cells with DANCR overexpression were revealed with Transwell assay and Matrigel assay, respectively (right panel). Typical images are shown in the left panel. *P<0.05. **Abbreviations:** DANCR, differentiation antagonizing nonprotein coding RNA; PDAC, pancreatic ductal adenocarcinoma; qRT-PCR, quantitative real time polymerase chain reaction.

Conclusion

Increasing data suggest that lncRNAs play pivotal roles in the progression of PDAC, which indicated that lncR-NAs were involved in tumor growth, survival, epithelial– mesenchymal transition (EMT), tumor microenvironment, cancer stem cells (CSCs) and chemoresistance in PDAC.²⁵ lncRNAs can mediate the expression of miRNA-targeted genes through functioning as miRNA sponge.^{26,27} EMT is




Figure 4 DANCR increases proliferation of PDAC cells. Notes: (A) Colony formation assay was performed to verify the n ability anc1 cells after DANCR silencing. The 50–100/100–200/>200 brackets represent cell numbers in each colony. (B) The proliferation ability of Panc is with ANCR d ency was evaluated by CCK-8 assay. (C) Colony formation assay was performed to verify the proliferation ability of BxPC3 cells after DANCR or xpression, e 50–100 –200/>200 brackets represent cell numbers in each colony. (D) The proliferation ability of BxPC3 cells with DANCR overexpression was eva d by C Abbreviations: CCK-8, Cell Counting Kit-8; DANCE nprotein coding RNA; h, hour(s); PDAC, pancreatic ductal adenocarcinoma. ffer ntagonizing

an initial step in cancer metasta 28 F umulating adies of PDAC.^{29–32} found that lncRNAs particip e in the EN sulator of reprogramming was For example, lncRNA reported to promote the aggres ve biological behaviors of PDAC by acting as a regul of ZEP, which is a primary transcriptional the EA p gress, and thus increase .ctor stasis of MAC.²⁹ CSCs are also an the invasio and me which InerNAs exert their functions in important way lopment of PDAC.^{33,34} Chemoradioresismodulating the de tance is an essential ason leading to the relapse of cancer patients. Multiple studies have focused on the potential role of lncRNAs in chemoradioresistance.35-39 Combination of IncRNAs and conventional chemotherapeutic reagents is considered as a promising way for improving the sensitivity of adjuvant therapy.³⁹ There are also studies that revealed that lncRNAs could modulate the epigenetic modifications and autophagy in PDAC.⁴⁰⁻⁴² Obviously, IncRNAs can function in a wide range of cancer biology; however, clinical

trials investigating lncRNAs in the treatment of PDAC are rare, and further studies are needed for utilizing lncRNAs in clinical practice.

Since being discovered in 2012,¹⁷ DANCR has attracted much attention for its critical role in cancer biology. DANCR is now regarded as an oncogene for promoting cancer growth and metastasis in hepatocellular carcinoma,⁴³ glioma,²⁴ gastric cancer,⁴⁴ osteosarcoma,²³ lung adenocarcinoma,²² prostate cancer²¹ and colorectal cancer.⁴⁵ DANCR was also implicated to be a diagnostic and prognostic marker.^{19,20,43} Mechanistically, DANCR could directly interact with miR-634 and this interaction resulted in the inhibition of RAB1A expression, thus accelerating the progression of glioma.²⁴ By competitively binding to miR-33a-5p, DANCR could upregulate the expression of the receptor tyrosine kinase AXL and increase the function of CSCs in osteosarcoma.²³ The mechanisms of DANCR mediating cancer progression are relatively rare, which deserves further investigations.




Figure 5 DANCR functions through upregulating AXL via microRNA-33a inhi Notes: (A) Expression of miR-33a-5p and miR-634 was measured by gRT CR in detected by qRT-PCR in BxPC3 cells with DANCR overexpression of miR-33a-5p and miR-634 was measured by qRT-PCR in Panc1 cells with DANCR (**C**) Exp deficiency. (D) Expression of AXL and RABIA was detected CR in Pa cells with DANCR deficiency. *P < 0.05Abbreviations: DANCR, differentiation antagonizing n rotein co ng RNA;

PCR, quantitative real time polymerase chain reaction.

This study discovered that NCR was rerexpressed in PDAC tissues compared with mor-adjacent tissues. Further detection found at high DA CR expression was ar invasion (P=0.23), advanced T correlated with vase stage (P=0.005), mph r Ae metastasis (P < 0.001) and < 0.001 _____ of which are critical advanced TNM stage ssion and prognosis. Morefactors ev atin ancer 09 1 DAN expression correlated with poor OS and over, h PFS. Muk ate analysis identified high DANCR expression as an inc endent survival risk factor for OS and PFS. In addition, DACR was confirmed to facilitate growth and metastasis of PDAC cells. These results indicated that DANCR is a promising prognostic marker and therapeutic target in PDAC. In addition, DANCR may function through upregulating AXL via microRNA-33a-5p inhibition.

In conclusion, our study confirmed the overexpression of DANCR in PDAC cells and tissues. The clinical significance and prognostic value of DANCR were also detected. In vitro assays demonstrated the oncogenic role of DANCR. These observations demonstrated that DANCR plays a crucial role in the progression of PDAC, and DANCR might potentially serve as a prognostic marker and therapeutic target for PDAC patients.

with DANCR overexpression. (B) Expression of AXL and RABIA was

Disclosure

The author reports no conflicts of interest in this work.

References

- 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.
- 2. Gupta R, Amanam I, Chung V. Current and future therapies for advanced pancreatic cancer. J Surg Oncol. 2017;116(1):25-34.
- Malesci A, Tommasini MA, Bonato C, et al. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology. 1987;92(1):60-67.
- 4. Paganuzzi M, Onetto M, Marroni P, et al. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer. 1988;61(10): 2100-2108.
- 5. Loosen SH, Neumann UP, Trautwein C, Roderburg C, Luedde T. Current and future biomarkers for pancreatic adenocarcinoma. Tumour Biol. 2017; 39(6):1010428317692231.

- 6. Chen LL, Carmichael GG. Long noncoding RNAs in mammalian cells:
- what, where, and why? *Wiley Interdiscip Rev RNA*. 2010;1(1):2–21.
 7. Lipovich L, Johnson R, Lin CY. MacroRNA underdogs in a microRNA world: evolutionary, regulatory, and biomedical significance of mammalian long non-protein-coding RNA. *Biochim Biophys Acta*. 2010;1799(9):597–615.
- Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. *Cell*. 2009;136(4):629–641.
- Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81:145–166.
- Flynn RA, Chang HY. Long noncoding RNAs in cell-fate programming and reprogramming. *Cell Stem Cell*. 2014;14(6):752–761.
- Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. *Cell*. 2013;152(6):1298–1307.
- Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ. Targeting noncoding RNAs in disease. J Clin Invest. 2017;127(3):761–771.
- Evans JR, Feng FY, Chinnaiyan AM. The bright side of dark matter: IncRNAs in cancer. J Clin Invest. 2016;126(8):2775–2782.
- Bartonicek N, Maag JL, Dinger ME. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. *Mol Cancer*. 2016;15(1):43.
- Cabili MN, Trapnell C, Goff L, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. *Genes Dev.* 2011;25(18):1915–1927.
- Chandra Gupta S, Nandan Tripathi Y. Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. *Int J Cancer*. 2017;140(9):1955–1967.
- Kretz M, Webster DE, Flockhart RJ, et al. Suppression of progenitor differentiation requires the long noncoding RNA ANCR. *Genes Dev.* 2012;26(4):338–343.
- Yuan SX, Wang J, Yang F, et al. Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. *Hepatology*. 2016;63(2):499–511.
- Hao YP, Qiu JH, Zhang DB, Yu CG. Long non-coding RNA DANC a prognostic indicator, promotes cell growth and tumorigenicity in gastric cancer. *Tumour Biol.* 2017;39(6):1–9.
- Liu Y, Zhang M, Liang L, Li J, Chen YX. Over-expression on RNA DANCR is associated with advanced tumor progress on and popprognosis in patients with colorectal cancer. *Int J Che Exp Pather* 1915, 8(9):11480–11484.
- Jia J, Li F, Tang XS, et al. Long noncodin, RNA DA, P. promotes invasion of prostate cancer through or so ptically silence expression of TIMP2/3. *Oncotarget*. 2016, 225):35, 8–37881.
- Lu QC, Rui ZH, Guo ZL, et al. J CRNA-DANG contributes to lung adenocarcinoma progression in sponging miR-496 condulate mTOR expression. J Cell Mol Mar 2018;22(1):1527–1537.
- Jiang N, Wang X, Xie X, Stal. IncParA DANCR promotes tumor progression and cancer stemme. See ares in oster arcoma by upregulating AXL via miR-32 Combibility. *Cancer via*. 2017;405:46–55.
- 24. Xu D, Yu J, Co G, et al. LncRN, D4, CR functions as a competing endogenous kNA to realize RAB1X expression by sponging miR-634 in glioma. *Sci Realize Competitional BSR20171664*.
- Duguang L, Jhang Ciaowei Q, et al. The involvement of lncRNAs in the development and engression of pancreatic cancer. *Cancer Biol Ther*. 2017;18(12):927–93.
- Zhang X, Gao F, Zhou L, et al. UCA1 Regulates the Growth and Metastasis of Pancreatic Cancer by Sponging miR-135a. *Oncol Res.* 2017; 25(9):1529–1541.
- Wang G, Pan J, Zhang L, Wei Y, Wang C. Long non-coding RNA CRNDE sponges miR-384 to promote proliferation and metastasis of pancreatic cancer cells through upregulating IRS1. *Cell Prolif.* 2017; 50(6):e12389.

- Geiger TR, Peeper DS. Metastasis mechanisms. *Biochim Biophys Acta*. 2009;1796(2):293–308.
- Zhan HX, Wang Y, Li C, et al. LincRNA-ROR promotes invasion, metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway. *Cancer Lett.* 2016;374(2):261–271.
- Wu BQ, Jiang Y, Zhu F, Sun DL, He XZ. Long Noncoding RNA PVT1 Promotes EMT and Cell Proliferation and Migration Through Downregulating p21 in Pancreatic Cancer Cells. *Technol Cancer Res Treat*. 2017;16(6):819–827.
- 31. Chen S, Zhang JQ, Chen JZ, et al. The over expression of long noncoding RNA ANRIL promotes epithelial-mesenchymal transition by activating the ATM-E2F1 signaling pathway in pancreatic cancer: An in vivo and in vitro study. *Int J Biol Macromol*. 2017;102:718–728.
- 32. Li H, Wang X, Wen C, et al. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hyperbasic induced epithelialmesenchymal transition to promote metric asis in procreatic cancer. *Mol Cancer*. 2017;16(1):169.
- Jiao F, Hu H, Han T, et al. Long noncology RNA MALA 11 enhances stem cell-like phenotypes in part ratic call recells. *Int J vol Sci.* 2015; 16(4):6677–6693.
- Fu Z, Chen C, Zhou Q, et al. LncP A HOT produlates cancer stem cell properties in hump paner and cancer by regulating HOXA9. *Cancer Lett.* 2017; pp:68–6.
- 35. Jiang Y, Li Z, Zhang S, et al. the long con-coding RNA HOTAIR affects the react estivity of part and ductal adenocarcinoma by regulating the expression of Wnt inhibitory factor 1. *Tumour Biol.* 2016; 37(3):3957–3967.
- Wyger, L., Jong P, Wang Huang M, Tian B. Gemcitabine treattrant causes resistance and malignancy of pancreatic cancer stem-like Ils via induction of IncRNA HOTAIR. *Exp Ther Med.* 2017;14(5): 73–4780.
- G. YQ, Wang P, Chen DH, et al. Long non-coding RNA GAS5 antagonizes. The acresistance of pancreatic cancer cells through downorgulation of miR-181c-5p. *Biomed Pharmacother*. 2018;97:809–817.
- 38 21. Tao X, Zhou Y, et al. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. *J Transl Med.* 2015;13:84.

2. Xiong G, Feng M, Yang G, et al. The underlying mechanisms of noncoding RNAs in the chemoresistance of pancreatic cancer. *Cancer Lett.* 2017;397:94–102.

- Li C, Zhao Z, Zhou Z, Liu R. Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis. *Cancer Chemother Pharmacol.* 2016; 78(6):1199–1207.
- Qian K, Liu G, Tang Z, et al. The long non-coding RNA NEAT1 interacted with miR-101 modulates breast cancer growth by targeting EZH2. Arch Biochem Biophys. 2017;615:1–9.
- 42. Lian Y, Wang J, Feng J, et al. Long non-coding RNA IRAIN suppresses apoptosis and promotes proliferation by binding to LSD1 and EZH2 in pancreatic cancer. *Tumour Biol.* 2016;37(11):14929–14937.
- Ma X, Wang X, Yang C, et al. DANCR Acts as a Diagnostic Biomarker and Promotes Tumor Growth and Metastasis in Hepatocellular Carcinoma. *Anticancer Res.* 2016;36(12):6389–6398.
- Mao Z, Li H, du B, et al. LncRNA DANCR promotes migration and invasion through suppression of lncRNA-LET in gastric cancer cells. *Biosci Rep.* 2017;37(6):BSR20171070.
- Tong X, Gu PC, Xu SZ, Lin XJ. Long non-coding RNA-DANCR in human circulating monocytes: a potential biomarker associated with postmenopausal osteoporosis. *Biosci Biotechnol Biochem*. 2015;79(5): 732–737.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal

Dovepress

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.